Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Overview
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Bio-Pharm Solutions Co Ltd
Domain Therapeutics SA
Nobias Therapeutics Inc
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Drug Profiles
ADX-71743 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DT-095435 - Drug Profile
Product Description
Mechanism Of Action
JBPOS-0101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LSP-29166 - Drug Profile
Product Description
Mechanism Of Action
NB-001 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Agonize mGlu7 for Rett Syndrome - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Dormant Products
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Discontinued Products
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Product Development Milestones
Featured News & Press Releases
Jul 09, 2019: Addex to lead mGlu7 M-focused PTSD consortium
Jun 13, 2016: Addex mGluR7 Program Demonstrate Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases
Nov 23, 2015: Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR7 Allosteric Modulator for Neurodegenerative and Psychiatric Diseases
Dec 20, 2012: Addex Scientists Discover And Characterize First Potent And Selective Small Molecule Negative Allosteric Modulator Targeting mGlu7 Receptor
Oct 02, 2012: Addex Therapeutics And Collaborators Receive CHF700,000 Grant To Develop Allosteric Modulators For Neurodegenerative And Psychiatric Diseases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Addex Therapeutics Ltd, 2022
Pipeline by Bio-Pharm Solutions Co Ltd, 2022
Pipeline by Domain Therapeutics SA, 2022
Pipeline by Nobias Therapeutics Inc, 2022
Dormant Projects, 2022
Discontinued Products, 2022